Understand the source comparison
Best Peptides for Chronic Fatigue Syndrome: Mechanism Comparison
Thymalin Thymic peptide signalling, T-cell regulation Immune-dominant (elevated cytokines, NK cell dysfunction) 2–3x weekly subcutaneous Moderate (published cytokine normalisation data in post-viral fatigue) Best first-line choice for patients with documented
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- Thymic peptide signalling, T-cell regulation
- Immune-dominant (elevated cytokines, NK cell dysfunction)
- 2–3x weekly subcutaneous
- Moderate (published cytokine normalisation data in post-viral fatigue)
- Best first-line choice for patients with documented immune dysregulation. Requires baseline cytokine panel to confirm target mechanism
- Cerebrolysin
- BDNF mimetic, TrkB receptor activation
- Neurological-dominant (brain fog, cognitive impairment)
- 5–10 mL IV 3x weekly
- Strong (clinical trials in stroke recovery, cognitive impairment)
- Most robust evidence for reversing cognitive symptoms. Requires IV administration, which limits accessibility
- Dihexa
- HGF receptor activation, mitochondrial biogenesis
- Neurological + metabolic overlap (brain fog + exercise intolerance)
- Daily oral or subcutaneous
- Emerging (animal models show sustained cognitive enhancement)
- Dual-pathway targeting makes it valuable for mixed-subtype CFS. Human trials still limited
- MK-677
- Ghrelin receptor agonist, GH/IGF-1 secretagogue
- Metabolic-dominant (muscle weakness, impaired recovery)
- Daily oral
- Moderate (clinical trials in sarcopenia, GH deficiency)
- Effective for restoring anabolic signalling but doesn't directly address immune or mitochondrial dysfunction. Best as adjunct therapy
- P21
- CNTF analogue, long-term potentiation
- Neurological-dominant (memory consolidation deficits)
- 2–3x weekly intranasal
- Weak (primarily animal data, minimal human trials)
- Promising for sustained cognitive improvement but lacks robust human evidence. Higher-risk investigational choice
- CJC-1295/Ipamorelin
- GH secretagogue combination, extended half-life
- Metabolic-dominant (tissue repair, sleep disruption)
- 3–5x weekly subcutaneous
- Moderate (GH secretion confirmed, CFS-specific trials absent)
- Produces stable GH elevation without cortisol spikes. Valuable for patients intolerant to pulsatile GH protocols